<DOC>
	<DOCNO>NCT03081702</DOCNO>
	<brief_summary>This phase I/II study find high dose hydroxychloroquine give safely itraconazole patient advance platinum-resistant epithelial ovarian cancer . The study also determine safety , tolerability , initially determine whether combination useful treatment patient advance platinum-resistant epithelial ovarian cancer .</brief_summary>
	<brief_title>A Study Safety , Tolerability Effectiveness Hydroxychloroquine Itraconazole Platinum-resistant Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Aged 18 year old . Histologically cytologically confirm epithelial ovarian cancer . Platinumresistant refractory disease define radiological clinical progression less six month finish platinumbased chemotherapy . ECOG performance status equal less 1 . Have clinically radiographically document measurable disease . All systemic therapy must complete 4 week great prior enrollment radiologic evidence radiological disease progression . Life expectancy 3 month . Receiving medication substance inhibitor inducer CYP3A4 ineligible . Acceptable laboratory requirement within 7 day prior enrollment Treated asymptomatic brain metastasis eligible . Patients receive palliative radiation ( brain metastasis ) eligible asymptomatic least 2 week use maintenance steroid therapy , last received radiation least 4 week prior start therapy . Have ability understand willing sign write informed consent document . Have recover ( grade 1 less ) adverse event relate previous treatment exclude exception alopecia lymphopenia . Peripheral sensory neuropathy must grade 2 less . Have prior malignancy patient disease free less 3 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ site cancer . History allergic reaction attribute compound similar chemical biologic composition itraconazole hydroxychloroquine . Known G6PD deficiency due risk hemolytic anemia use hydroxychloroquine . Known retinopathy due risk worsen retinopathy hydroxychloroquine . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic asymptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Chronic Hepatitis B hepatitis C infection exclude potential effect hepatic function and/ drug interaction . Human Immunodeficiency Virus ( HIV ) infection . Already clinical indication treatment itraconazole ( e.g . chronic candidiasis fungal infection ) hydroxychloroquine ( e.g . lupus ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>